Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 500 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus ( Type 1 and Type 2) Clear all

Conditions: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
Interventions: Not listed
Lead sponsor: InLight Solutions; Industry
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Diabetes Mellitus
Interventions: EGT0001442, Placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Buena Park, California • Los Angeles, California • Santa Ana, California + 8 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 46
States / cities: Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more

Conditions: Diabetes Mellitus
Interventions: Inhaled Human Insulin, Regular Human Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Continuous Glucose Monitoring
Interventions: Virtual CGM initiation service, Online educational module on CGM, Practice facilitation; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions: Adipose tissue biopsy; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 6
States / cities: Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Continuous Glucose Monitoring System; Device
Lead sponsor: Senseonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Escondido, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Hydrochlorothiazide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes, Gastroparesis
Interventions: PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION, Sham percutaneous electrical nerve field stimulation; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 39
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 35 more

Conditions: Type 2 Diabetes Mellitus
Interventions: HM12460A; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Type 1, Diabetes, Type 2, Cardiovascular Disease, Hyperglycemia
Interventions: Modified Carbohydrate Breakfast, Control Breakfast; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions: multi-component nutritional supplement capsules, multi-component dietary supplement; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy Volunteers
Interventions: Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 1 Diabetes
Interventions: Simvastatin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 20 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Type 1 Diabetes
Interventions: Alprazolam, control group; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions: PI-2620 tracer; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 2 Diabetes Mellitus
Interventions: AC-201, 25mg, AC-201, 50mg, AC-201, 75mg, Placebo; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Chino, California • Los Angeles, California • Coral Gables, Florida + 10 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Lispro low mixture; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 13
States / cities: La Jolla, California • Walnut Creek, California • New Britain, Connecticut + 10 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions: Technosphere Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 25
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more

Search by objective public record fields.

Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Implementing Continuous Glucose Monitoring in Primary Care for Patients With Diabetes

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Adipose Tissue Function After Pancreas Transplantation

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Effect Of Percutaneous Electrical Nerve Field Stimulation on Symptom Control/Nervous System Activity in Patients w/Diabetes Types 1/2

Afrezza® INHALE-1 Study in Pediatrics

Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

Breakfast Nutrition and Inpatient Glycemia

Diabetes Visual Function Supplement Study

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma